An observational study in Colorectal Cancer Metastatic, Brain Metastases, Adult and Ras (KRAS or NRAS) Gene Mutation, sponsored by Blokhin's Russian Cancer Research Center. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Blokhin's Russian Cancer Research Center · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Brain Neoplasms with a site in Russia — 6 open to participants now, 9 under way, none of them phase 3. Brain Neoplasms · Russia.
Among the 10 studies in Brain Neoplasms with a site in Russia, this one is the only one that started in 2024, is one of 4 observational ones, and was the 6th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →6 of the 10 studies in Brain Neoplasms with a site in Russia are open now. Recruiting first, the newest first:
Blokhin's Russian Cancer Research Center · Sites in Russia
Ages 18+
Sklifosovsky Institute of Emergency Care · Sites in Russia
Ages 18–80
Sklifosovsky Institute of Emergency Care · Sites in Russia
Ages 18–80
Sklifosovsky Institute of Emergency Care · Sites in Russia
Ages 18–80
Apollomics Inc. · Sites in Russia, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2017; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 99 across 433 observational studies indexed under Brain Neoplasms.
Median enrollment 100 across the 6 interventional studies, 130 across the 4 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 5 most frequent:
Blokhin's Russian Cancer Research Center is the lead sponsor of 34 studies on the registry; 17 are open to participants now.
Blokhin's Russian Cancer Research Center has 4 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Brain Neoplasms with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05474573Sklifosovsky Institute of Emergency CareConcurrent Fluorescence and Sonographically Guided Eradication of High-grade Gliomas and Metastases | 2027-08-31 |
| NCT05477680Sklifosovsky Institute of Emergency CareIntraoperative Brain Shift Calculation Study | 2027-08-31 |
| NCT05484245Sklifosovsky Institute of Emergency CareSonography-guided Resection of Brain Mass Lesions | 2027-08-31 |
| NCT06449989Blokhin's Russian Cancer Research CenterComparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer | 2027-09 |
| NCT07448662Blokhin's Russian Cancer Research CenterLocal Treatment Strategies for Brain Metastases of Colorectal Cancer | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 10 studies in Brain Neoplasms with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GENCONCOR-1 study is translational research aimed to investigate the concordance of the molecular genetic profile of the primary tumor and brain metastases (BM) of colorectal cancer (CRC). The study was conducted by post hoc analysis of pairs of samples of histological material with determination of the mutational status of genes KRAS, NRAS, BRAF, HER2 and MSI.
Brain metastases (BM) from colorectal cancer (CRC) are a rare event reported in less than 3% of patients with CRC (the reported incidence ranges from 0.27 to 3%). This course is associated with a poor prognosis. Treatment of these patients remains challenging. Nevertheless, given the rarity of the event, at this time not enough is known about molecular biology of BM from colorectal cancer and its concordance with matched primary tumors.
In N.N. Blokhin National Medical Research Center of Oncology over 26 years (1998-2024) identified 108 patients with BM from CRC. Of this number, 72 patients had a history of neurosurgical resection of BM. In turn, for 32 patients access to a pair of tumor samples: from the primary tumor and from intracranial metastases. Tumor samples will be tested for mutation status of genes KRAS, NRAS, BRAF, HER2 and MSI. Analysis was limited to this pool of genes because of their clinical relevance and potential prognostic information. The molecular profile of the BM will be compared with the corresponding primary tumor with calculation of concordance rate (%).
Patients with metastatic colorectal cancer (CRC) and brain metastases (BM) will be analyzed according to sex, age, functional status (ECOG 0-1 or 2-3), number of BM (solitary or ≥ 2), clinical manifestations of BM (symptomatic or asymptomatic), extracranial lesions at the time of diagnosis BM (present or absent), course of brain metastases (synchronous with the primary tumor or metachronous), side of the location of the primary tumor (left-sided or right-sided CRC), location of intracranial lesions (supratentorial or subtentorial), number of previous lines of drug therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For molecular genetic research, archival formalin-fixed and paraffin-embedded tumor blocks will be used. Research method - HRM-PCR sequencing to determine mutation status of KRAS, NRAS and BRAF (RotorGene 6000, ABI Prism 3500) and fragmentation analysis to determine MSI (ABI Prism 3500) Subject to study: mutations in the KRAS, NRAS, BRAF genes, as well as MSI status and HER2neu expression (± amplification) Somatic mutations in the RAS family genes are planned to be studied in exons 2 (codons 12 and 13), exon 3 (codon 61) and exon 4 (codon 146). In the case of the BRAF gene - exon 15 (codons 597-601). Determination of microsatellite instability is planned using five markers: BAT25, BAT26, NR21, NR24, NR27, associated with structural and functional disorders of the DNA unpaired base repair system. Assessment of HER2 gene status is planned by immunohistochemical (IHC) screening of HER2neu expression. IHC-screening of HER2-status will be performed using an antibody clone 4B5 (Ventana).
Concordance rate (%)
Concordance rate (%) between mutational status of the brain lesions and their corresponding primary tumor. Calculated as the ratio of concordant cases to total cases.
Time frame: 1 month
Intracranial progression-free survival (CNS-PFS1)
Time from the date of cancer diagnosis to the date of detection of brain metastases.
Time frame: 3 months
Overall survival (OS)
Time from the date of detection of brain metastases to the date of death.
Time frame: 6 months
Intracranial progression-free survival (CNS-PFS2)
Time from the date of neurosurgical resection to the date of intracranial progression (continued growth or distant brain metastases) or death.
Time frame: 3 months
Plan to share: Yes — Individual participant data that underline the results reported in article, after deidentification (text, tables, figures, and appendices)
Time frame: From the moment of publication of the results and indefinitely
Access criteria: For individual participant data meta-analysis. Data will be available indefinitely in the appendix of the published article
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Blokhin's Russian Cancer Research Center